

eTable 2. Treatment characteristics of patients with LGI1E

Characteristics	Patients, no. (%) LGI1E (n = 34)
Immunotherapy	
First-line immunotherapy	33/33 (100)
Corticosteroids	32/33 (97)
Therapeutic apheresis	19/33 (58)
Intravenous immunoglobulins	12/33 (36)
Second-line immunotherapy	24/31 (77)
Rituximab	22/31 (71)
Azathioprine	2/31 (6)
Third-line immunotherapy	1/31 (3)
Bortezomib	1/31 (3)
Immunotherapy exposure at study visits	
First study visit (34)	27/29 (93)
Second study visit (14)	4/12 (33)
Third study visit (4)	1/3 (33)
Antiseizure therapy	28/33 (85)
Antipsychotic and/or antidepressant therapy	15/33 (45)

Data are presented as number/total number (%) of patients with available information.